Literature DB >> 8709239

The structurally diverse intergenic regions of respiratory syncytial virus do not modulate sequential transcription by a dicistronic minigenome.

L Kuo1, R Fearns, P L Collins.   

Abstract

The first nine genes of respiratory syncytial virus (RSV), a nonsegmented negative-strand RNA virus, are separated by intergenic regions which range in size from 1 to 52 nucleotides for strain A2 and lack obvious consensus elements except that each ends in an A (genome sense). Their significance for gene expression was investigated by using RSV-CAT-LUC RNA, a helper-dependent cDNA-encoded dicistronic analog of RSV genomic RNA in which the viral genes were replaced by a negative-sense copy of the translational open reading frame (ORF) encoding chloramphenicol acetyltransferase (CAT) as the upstream, leader-proximal gene and that encoding luciferase (LUC) as the downstream gene. These foreign ORFs were flanked by the RSV gene-start (GS) and gene-end (GE) transcription signals and separated by the naturally occurring G/F intergenic region. The RSV-CAT-LUC minigenome was synthesized in vitro and transfected into RSV-infected cells, and synthesis of the CAT and LUC mRNAs was monitored by enzyme assay and Northern (RNA) blot hybridization. Surprisingly, substitution of each of the other naturally occurring RSV intergenic regions in turn did not significantly alter the absolute or relative amounts of the two mRNAs. Substitution of a nonnatural 10-nucleotide intergenic region, or elimination of the intergenic region altogether, also had little effect on the level of expression of the two genes. Four of the minigenome variants containing naturally occurring intergenic regions were modified further by replacing part of the LUC ORF with a second copy of the CAT ORF, so that each of the two mRNAs would hybridize equally with a CAT-specific probe and their relative molar amounts could be determined. The level of expression of the downstream gene was 0.30 to 0.36 that of the upstream one. This determined the magnitude of RSV transcriptional polarity across a gene pair and confirmed that this value was very similar among the various intergenic regions. Minigenome transcription also yielded a CAT-LUC readthrough mRNA at a level 0.10 to 0.13 that of the LUC mRNA. In summary, the structurally diverse RSV intergenic regions do not appear to play a role in modulating RSV gene expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709239      PMCID: PMC190637          DOI: 10.1128/JVI.70.9.6143-6150.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Polytranscripts of Sendai virus do not contain intervening polyadenylate sequences.

Authors:  K C Gupta; D W Kingsbury
Journal:  Virology       Date:  1985-02       Impact factor: 3.616

2.  Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus.

Authors:  P L Collins; R A Olmsted; M K Spriggs; P R Johnson; A J Buckler-White
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness.

Authors:  P R Johnson; P L Collins
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

4.  cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus.

Authors:  P L Collins; G W Wertz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

5.  Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes.

Authors:  P L Collins; Y T Huang; G W Wertz
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

6.  Transcriptional mapping of human respiratory syncytial virus.

Authors:  L E Dickens; P L Collins; G W Wertz
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

7.  RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end.

Authors:  S K Samal; P L Collins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription.

Authors:  L E Iverson; J K Rose
Journal:  Cell       Date:  1981-02       Impact factor: 41.582

9.  Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order.

Authors:  P L Collins; L E Dickens; A Buckler-White; R A Olmsted; M K Spriggs; E Camargo; K V Coelingh
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

10.  Detection of in vivo synthesis of polycistronic mRNAs of vesicular stomatitis virus.

Authors:  P S Masters; C E Samuel
Journal:  Virology       Date:  1984-04-30       Impact factor: 3.616

View more
  34 in total

1.  The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication.

Authors:  P L Atreya; M E Peeples; P L Collins
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

2.  Analysis of the gene start and gene end signals of human respiratory syncytial virus: quasi-templated initiation at position 1 of the encoded mRNA.

Authors:  L Kuo; R Fearns; P L Collins
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.

Authors:  U J Buchholz; H Granzow; K Schuldt; S S Whitehead; B R Murphy; P L Collins
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Analysis of the highly diverse gene borders in Ebola virus reveals a distinct mechanism of transcriptional regulation.

Authors:  Kristina Brauburger; Yannik Boehmann; Yoshimi Tsuda; Thomas Hoenen; Judith Olejnik; Michael Schümann; Hideki Ebihara; Elke Mühlberger
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

5.  Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase.

Authors:  Michel Liuzzi; Stephen W Mason; Mireille Cartier; Carol Lawetz; Robert S McCollum; Nathalie Dansereau; Gordon Bolger; Nicole Lapeyre; Yvon Gaudette; Lisette Lagacé; Marie-Josée Massariol; Florence Dô; Paul Whitehead; Lyne Lamarre; Erika Scouten; Josée Bordeleau; Serge Landry; Jean Rancourt; Gulrez Fazal; Bruno Simoneau
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 6.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  The length and sequence composition of vesicular stomatitis virus intergenic regions affect mRNA levels and the site of transcript initiation.

Authors:  E A Stillman; M A Whitt
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Transcriptional Regulation in Ebola Virus: Effects of Gene Border Structure and Regulatory Elements on Gene Expression and Polymerase Scanning Behavior.

Authors:  Kristina Brauburger; Yannik Boehmann; Verena Krähling; Elke Mühlberger
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

9.  Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

Authors:  S S Whitehead; C Y Firestone; R A Karron; J E Crowe; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Model for polymerase access to the overlapped L gene of respiratory syncytial virus.

Authors:  R Fearns; P L Collins
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.